- Home
- ICLR vs BBIO Comparison
ICLR vs BBIO Comparison
Compare ICLR & BBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ICLR | BBIO |
|---|---|---|
| Founded | 1990 | 2015 |
| Country | Ireland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Commercial Physical & Biological Resarch | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.8B | 15.3B |
| IPO Year | 1998 | 2019 |
Fundamental Metrics
Financial Performance| Metric | ICLR | BBIO |
|---|---|---|
| Price | $151.96 | $67.72 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 13 | 21 |
| Target Price | ★ $202.31 | $78.81 |
| AVG Volume (30 Days) | 953.9K | ★ 3.2M |
| Earning Date | 02-23-2026 | 02-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.47 | N/A |
| Revenue | ★ $8,102,602,000.00 | $353,780,000.00 |
| Revenue This Year | N/A | $129.08 |
| Revenue Next Year | $0.22 | $79.33 |
| P/E Ratio | $20.15 | ★ N/A |
| Revenue Growth | N/A | ★ 62.46 |
| 52 Week Low | $125.10 | $28.33 |
| 52 Week High | $211.00 | $81.33 |
Technical Indicators
Market Signals| Indicator | ICLR | BBIO |
|---|---|---|
| Relative Strength Index (RSI) | 22.55 | 41.53 |
| Support Level | $144.27 | $62.84 |
| Resistance Level | $191.00 | $80.00 |
| Average True Range (ATR) | 7.66 | 3.54 |
| MACD | -4.65 | -1.27 |
| Stochastic Oscillator | 2.06 | 40.90 |
Price Performance
Historical ComparisonAbout ICLR ICON plc
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
About BBIO BridgeBio Pharma Inc.
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis), is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.